Research To Practice | Oncology Videos

Featuring an interview with Dr Eric Sherman, including the following topics: Changes in the incidence, mortality, and management of thyroid cancer in the past 20 years (0:00) Clinical presentation and histologic characteristics of thyroid cancer; genomic alterations associated with each histology (5:55) Initial management of thyroid cancer; current role of surgery and radioactive iodine in treatment algorithms (14:56) Current and future role of tumor biomarkers in treatment selection; emerging role of liquid biopsies in anaplastic thyroid cancer (20:23) Incidence and optimal treatment of brain metastases in patients with thyroid cancer; biologic rationale for tyrosine kinase inhibitors (TKIs) targeting VEGF and BRAF in thyroid cancer (24:20) Safety and tolerability of sorafenib and lenvatinib; management of BRAF-mutated disease (34:49) Management of tumors in patients with RET alterations or NTRK fusions; therapies for medullary tumors (39:28) Case: A woman in her early 60s with metastatic papillary thyroid cancer; ongoing research combining TKIs and immunotherapy for anaplastic thyroid cancer (50:35) Case: A man in his early 40s presenting with severe diarrhea and metastatic medullary thyroid cancer (1:00:54) CME information and select publications

Featuring perspectives from Prof Karim Fizazi and Prof Stéphane Oudard, including the following topics: Introduction: Journal Club — Karim Fizazi, MD, PhD and Stéphane Oudard, MD, PhD (0:00) Case: A man in his late 50s with Gleason 7 prostate cancer after prostatectomy/radiation therapy/androgen deprivation therapy (ADT) experiences biochemical recurrence 2 years later (PSA 0.5; doubling time 9 months) — Philip L Brooks, MD (10:58) Case: A man in his early 70s with a pacemaker presents with de novo metastatic hormone-sensitive prostate cancer (mHSPC) after cerebrovascular accident — Nasfat Shehadeh, MD (28:50) Case: A man in his late 40s with multiple medical comorbidities presents with de novo mHSPC (PSA 19.4) and responds to ADT/docetaxel — Gurveen Kaur, MD (47:00) Case: A man in his mid 60s with de novo mHSPC receives leuprolide, and PSA levels decrease from 865 ng/mL to 1.34 ng/mL — Joanna Metzner-Sadurski, MD (50:38) Case: A man in his late 50s with mHSPC receives leuprolide, experiences disease progression 1.5 years later and responds to abiraterone/prednisone but on liquid biopsy is found to have an AR T878 mutation — Niyati A Nathwani, MD (54:30) Case: A man in his mid 60s presents with de novo metastatic prostate cancer and experiences disease progression on ADT + docetaxel, now with progressive disease on abiraterone/prednisone; germline CHEK2 mutation — Syed F Zafar, MD (56:51) CME information and select publications

Featuring a slide presentation and related discussion from Dr Jeffrey Zonder, including the following topics: Overview of amyloid light chain (AL) amyloidosis (0:00) Case: An African American man in his late 70s with transthyretin amyloidosis (8:39) Staging and prognosis of AL amyloidosis (14:11) Evolution of the amyloidosis treatment paradigm (26:39) Case: A woman in her late 70s with relapsed lambda light chain amyloidosis (44:33) Emerging data with novel therapies for AL amyloidosis (47:38) Case: A man in his early 60s with relapsed lambda light chain amyloidosis (52:18) CME information and select publications

Featuring an interview with Dr Jeffrey Zonder, including the following topics: Biology and symptomology of primary amyloidosis (0:00) Staging and prognosis for patients with amyloid light chain (AL) amyloidosis (10:21) Supportive care for patients with advanced disease (16:25) Current amyloidosis treatment paradigm (21:49) Monoclonal antibody therapy for patients with AL amyloidosis (31:38) CME information and select publications

Featuring perspectives from Dr Daniel Pollyea, including the following topics: Introduction (0:00) Acute Myeloid Leukemia (AML), 2014 to 2022 (3:35) Defining AML versus Myelodysplastic Syndromes (6:06) Case: A man in his early 80s presenting with cytopenias and AML (8:56) Oral Decitabine/Cedazuridine (18:15) Management of Cytopenias with HMA (Hypomethylating Agent)/Venetoclax: Drug-Drug Interactions (26:43) HMA/Venetoclax for Younger Patients (39:56) Translational Biology of AML: New Agents and Treatment Strategies (44:08) Case: A man in his mid 70s with p53-mutated AML and complex karyotype (47:48) Anti-CD47 Antibody Magrolimab (51:08) Case: A woman in her early 60s with MLL-rearranged AML after receiving 7 + 3, FLAG-IDA and azacitidine/venetoclax (54:22) CME information and select publications

Featuring perspectives from Dr Paul Richardson, including the following topics: Introduction (0:00) Case: A man in his early 60s with newly diagnosed Stage II standard-risk multiple myeloma — Ranju Gupta, MD (29:31) Case: A woman in her early 70s with Stage IIIA multiple myeloma who receives lenalidomide/bortezomib/dexamethasone → autologous stem cell transplant (ASCT) and discontinues maintenance lenalidomide after 3 years — Erik Rupard, MD (34:16) Case: A woman in her early 70s with relapsed myeloma after tandem ASCT who receives cyclophosphamide/bortezomib/dexamethasone, achieves minimum residual disease negativity and is now on maintenance ixazomib — Zanetta S Lamar, MD (39:01) Case: A woman in her early 70s with triple-class refractory t(11;14) multiple myeloma — Hans Lee, MD (43:47) Case: A man in his mid 60s with high-risk relapsed multiple myeloma after carfilzomib/lenalidomide/dexamethasone (KRd) induction, ASCT, maintenance KRd and 2 additional lines of therapy — Muzaffar H Qazilbash, MD (46:05) Faculty Survey (52:29) Journal Club with Dr Richardson (60:57) CME information and select publications

Featuring a slide presentation and related discussion from Dr Ruben Mesa, including the following topics: Efficacy and safety of FDA-approved JAK inhibitors for the management of myelofibrosis (MF) (0:00) Emerging JAK inhibitors under Phase III evaluation for MF (6:59) Current guidelines and strategies for managing MF (13:53) Emerging data with novel agents and strategies for MF (17:31) Splenic response and symptomology in patients with MF (25:36) CME information and select publications

Featuring an interview with Dr Ruben Mesa, including the following topics: Managing myelofibrosis (MF) before the availability of ruxolitinib (0:00) Pathobiology and mutational profile of MF (7:33) Matching treatments to individual patients with MF (13:25) Case: A man in his early 70s with MF and worsening anemia (17:13) Case: A man in his late 60s initially diagnosed with polycythemia vera now with MF requiring therapy (23:15) Case: A woman in her mid 60s with MF that has a suboptimal response to first-line JAK inhibitor therapy (30:25) Efficacy and safety of novel agents and strategies for MF (35:40) CME information and select publications

Featuring perspectives from Drs Ursula Matulonis and Debra Richardson, including the following topics: PROLOGUE: Antibody-Drug Conjugates Across Oncology (0:00) Antibody-Drug Conjugates in Ovarian Cancer: Mirvetuximab Soravtansine (10:03) Antibody-Drug Conjugates in Ovarian Cancer: Upifitamab Rilsodotin (29:09) Tumor Treating Fields (41:35) PARP Inhibitor Update (47:29) CME information and select publications

Featuring a slide presentation and related discussion from Dr Toni Choueiri, including the following topics: Evolution in the management of renal cell carcinoma (RCC) (0:00) Adjuvant therapy for intermediate- or high-risk RCC (1:52) Front-line therapy for patients with metastatic RCC (8:39) New agents for the treatment of relapsed or refractory RCC (16:24) Mechanism of action and efficacy of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (19:56) CME information and select publications